Relmada Therapeutics (RLMD) Competitors

Relmada Therapeutics (NASDAQ:RLMD) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Which has more risk & volatility, RLMD or KPTI?

Relmada Therapeutics has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500.

Do analysts rate RLMD or KPTI?

Relmada Therapeutics presently has a consensus price target of $4.25, indicating a potential upside of 611.89%. Karyopharm Therapeutics has a consensus price target of $43.20, indicating a potential upside of 737.21%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Karyopharm Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is RLMD or KPTI more profitable?

Relmada Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -52.62%. Karyopharm Therapeutics' return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-129.80%	-112.06%
Karyopharm Therapeutics	-52.62%	N/A	-39.58%

Do institutionals and insiders believe in RLMD or KPTI?

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 20.7% of Relmada Therapeutics shares are owned by insiders. Comparatively, 3.0% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has preferable valuation and earnings, RLMD or KPTI?

Relmada Therapeutics has higher earnings, but lower revenue than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$98.79M	-$2.51	-0.24
Karyopharm Therapeutics	$142.13M	0.31	-$143.10M	-$13.26	-0.39

Does the media refer more to RLMD or KPTI?

In the previous week, Karyopharm Therapeutics had 5 more articles in the media than Relmada Therapeutics. MarketBeat recorded 11 mentions for Karyopharm Therapeutics and 6 mentions for Relmada Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.23 beat Relmada Therapeutics' score of 0.00 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Karyopharm Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer RLMD or KPTI?

Karyopharm Therapeutics received 527 more outperform votes than Relmada Therapeutics when rated by MarketBeat users. Likewise, 72.44% of users gave Karyopharm Therapeutics an outperform vote while only 37.78% of users gave Relmada Therapeutics an outperform vote.

Company	Underperform	Outperform
Relmada Therapeutics	Outperform Votes 17 37.78%	Underperform Votes 28 62.22%
Karyopharm Therapeutics	Outperform Votes 544 72.44%	Underperform Votes 207 27.56%

Summary

Karyopharm Therapeutics beats Relmada Therapeutics on 12 of the 17 factors compared between the two stocks.